10-K · August 7, 2026
Clorox retains a strong branded portfolio, with more than 80% of sales from No. 1 or No. 2 category brands, and the GOJO acquisition broadens its health-and-hygiene and B2B positioning. However, fiscal 2026 showed…
Earnings analysis · 10-Q
CLX earnings analysis
Filed November 2, 2026 · Our reading of the company's report
The latest report
Clorox delivered a strong earnings beat, with $1.905 billion of revenue and $1.55 diluted EPS versus consensus of $1.875 billion and $1.05, respectively. Revenue increased approximately 33% year over year but declined…
Read full summary
Clorox delivered a strong earnings beat, with $1.905 billion of revenue and $1.55 diluted EPS versus consensus of $1.875 billion and $1.05, respectively. Revenue increased approximately 33% year over year but declined approximately 2% sequentially, while the filing does not provide current-quarter gross margin, operating margin, free cash flow, or segment results in the supplied text. The fiscal 2027 outlook was maintained, but management expects results toward the low end and projects gross margin of approximately 41.5%, supporting a neutral rather than bullish assessment.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $1.55
What stood out
-
Revenue beat estimates
Revenue was $1.905 billion, up approximately 33% from $1.43 billion in the prior-year quarter and down approximately 2% from $1.95 billion in the immediately preceding quarter. Revenue exceeded consensus of $1.875 billion by approximately $30 million.
-
EPS materially exceeded consensus
Diluted EPS was $1.55 versus $0.65 in the prior-year quarter, an increase of $0.90, and exceeded the $1.05 consensus estimate by $0.50.
-
Fiscal-year guidance maintained
Fiscal 2027 diluted EPS guidance remained $5.41-$5.71, while adjusted EPS guidance remained $5.70-$6.00; management expects performance toward the low end of both ranges.
-
Updated margin outlook
Management updated its fiscal 2027 gross-margin outlook to approximately 41.5% and expects selling and administrative expenses to be approximately 15.5% of sales.
What to watch
-
Margin pressure persists
The revised gross-margin outlook of approximately 41.5% indicates continued margin pressure, while selling and administrative expenses are expected to be approximately 15.5% of sales.
-
Earnings skewed to low end
Management expects fiscal 2027 diluted EPS to be toward the low end of the $5.41-$5.71 range and adjusted EPS toward the low end of the $5.70-$6.00 range, limiting upside to the maintained outlook.
-
No new quantified risk update
The filing states that there were no material changes to market risk since June 30, 2026 and directs investors to the fiscal 2026 Form 10-K for risk-factor information; therefore, the 10-Q does not identify a quantified new risk-factor development.
Management's outlook
Management maintained fiscal 2027 diluted EPS guidance of $5.41-$5.71 and adjusted EPS guidance of $5.70-$6.00, but expects results closer to the low end. Gross margin is now expected to be approximately 41.5% and selling and administrative expenses approximately 15.5% of sales. No separate quarterly guidance was provided in the filing.
Earlier filings 4
10-Q · April 30, 2026
Clorox reported Q3 fiscal 2026 results showing revenue of $1.67 billion, flat compared to the prior year and a minor increase in diluted EPS to $1.64 from $1.50. The results reflect ongoing challenges in the operating…
10-K · August 8, 2025
Clorox’s FY2025 10-K presents a company with stable top-line scale ($7.1 billion in net sales) that delivered margin expansion and a 190% increase in diluted EPS year-over-year while continuing its IGNITE transformation…
10-Q · October 30, 2024
Clorox reported quarterly net sales of $1,762 million, up $376 million (+27.1%) versus $1,386 million in the prior-year quarter. Gross profit rose to $807 million (45.8% gross margin) and diluted EPS was $0.80 versus…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.